Reading CRDF? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CRDF free→Reading CRDF? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CRDF free→QuarterlyIQ Insights · CRDF
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. As previously disclosed, on May 19, 2026, Cardiff Oncology, Inc. (the “Company”) filed a lawsuit against Nerviano Medical Sciences S.r.l. (“NMS”) disputing NMS’s allegation that the Company materially breached the License Agreement dated March 13, 2017 between the Company and NMS (the “Agreement”) by declining to name NMS employee Dr. Barbara Valsasina as a joint inventor of the Company’s U.S. Pat. Nos. 12,144,813 and 12,263,173 (the “Cardiff Patent…
Other Events. On May 19, 2026, Cardiff Oncology, Inc. (the “Company”) filed a lawsuit against Nerviano Medical Sciences S.r.L (“NMS”) disputing NMS’s allegation that the Company materially breached its license agreement (Agreement) for onvansertib. The complaint, filed in the United States District Court for the Southern District of California, seeks injunctive relief requiring NMS to continue performing under the Agreement and a declaratory judgment that Cardiff did not breach the Agreement.…
Results of Operations and Financial Condition. On May 14, 2026, Cardiff Oncology, Inc. issued a press release announcing a business update and financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 9, 2026, Cardiff Oncology, Inc. (the “Company”) announced that Josh Muntner has been appointed the Company’s Chief Financial Officer effective April 6, 2026. Mr. Muntner’s base salary is $475,000 per year with a 40% annual discretionary bonus. In addition, Mr. Muntner was granted non-qualified stock options to purchase 486,650 shares of th…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. The information set forth above under
Entry into a Material Definitive Agreement. Previously on January 26, 2026, Cardiff Oncology, Inc. (the “Company”) disclosed that Dr. Mark Erlander, CEO and James Levine, CFO had stepped down from their respective roles at the Company as part of a strategic review. On March 27, 2026 (the “Separation Date”), the Company entered into separation agreements with each of Dr. Erlander and Mr. Levine. Pursuant to Dr. Erlander’s agreement, among other things, he will be paid (i) his base salary of $6…
Results of Operations and Financial Condition. On February 24, 2026, Cardiff Oncology, Inc. (the "Company") issued a press release announcing financial results for the full year ended December 31, 2025 and a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 27, 2026, Dr. Mark Erlander, Ph.D., CEO of Cardiff Oncology, Inc. (the “Company”), and James Levine, CFO of the Company stepped down from their respective roles at the Company as part of a strategic leadership review. The Board of Directors of the Company has appointed Dr. Mani Mohindru, a member of the Company’s Board of Directors, as i…
Results of Operations and Financial Condition. On November 6, 2025, Cardiff Oncology, Inc. (the "Company") issued a press release announcing company highlights and financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
Results of Operations and Financial Condition. On July 29, 2025, Cardiff Oncology, Inc. (the "Company") issued a press release announcing company highlights and financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 13, 2025, Dr. Fairooz Kabbinavar and Cardiff Oncology, Inc. (the “Company”) agreed that he would be stepping down from his position as Chief Medical Officer. Dr. Kabbinavar agreed to enter into an agreement pursuant to which he will provide advisory services to the Company from time to time. On June 17, 2025, the Company announced that it h…
Results of Operations and Financial Condition. On May 8, 2025, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the first quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
Results of Operations and Financial Condition. On February 27, 2025, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the fourth quarter ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.